文献速递慢阻肺

轻中度COPD伴与不伴肺气肿的临床与预后差异

Clinical and Prognostic Differences in Mild to Moderate COPD With and Without Emphysema.
PubMed 文献 · Chest · 2024-10-23

基于SPIROMICS队列989例轻中度COPD患者,按CT低密度区<5%分为伴肺气肿(EC)与不伴肺气肿(NEC)两组。EC组占43.3%,FEV1年下降与NEC组无显著差异,但生活质量恶化更明显、急性加重率更高(1.42倍),NEC组肺气肿进展更快。

要点

  • 轻中度COPD中43.3%存在CT肺气肿,EC组急性加重率显著高于NEC组。
  • EC组FEV1年下降与NEC组无显著差异,但生活质量恶化更明显。
  • NEC组肺气肿进展速度显著快于EC组。

核心结论

  • EC组FEV1下降未加速,但生活质量更差且急性加重率更高。
  • NEC亚型肺气肿进展更快。

研究设计与样本

  • 来自SPIROMICS队列的989例轻中度COPD患者临床数据分析。
  • 按基线CT低密度区<5%(<-950 HU)分为EC组与NEC组。
  • 采用线性混合效应模型评估肺功能、生活质量及定量CT指标变化。
  • 采用零膨胀负二项回归评估急性加重率。

主要发现

  • 428例(43.3%)存在CT肺气肿。
  • FEV1年下降EC组-56.1 mL/y,NEC组-46.9 mL/y,组间差异9.1 mL/y(95%CI -24.0至5.7 mL/y),无统计学意义。
  • EC组肺气肿进展速率显著低于NEC组(自然对数%LAA-950,-0.173%;95%CI -0.252%至-0.094%)。
  • EC组圣乔治呼吸问卷评分年增加比NEC组更明显(0.9分)。
  • EC组急性加重率0.36次/人年,NEC组0.25次/人年,率比1.42(95%CI 1.27-1.54)。

临床怎么用

  • 对轻中度COPD应关注CT肺气肿表型,EC组需加强急性加重预防与生活质量评估。
  • NEC组仍需监测肺气肿进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical and prognostic characteristics of mild-to-moderate COPD with and without emphysema remain inadequately investigated. RESEARCH QUESTION: Do the clinical and prognostic characteristics differ between mild-to-moderate COPD with and without emphysema? STUDY DESIGN AND METHODS: We obtained clinical data of 989 participants with mild-to-moderate COPD from the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS). They were categorized into two groups based on their baseline low-attention lung voxels with a density < -950 Hounsfield units of < 5% on CT scans: mild-to-moderate COPD with emphysema (EC) group and mild-to-moderate COPD without emphysema (NEC) group. Linear mixed-effects models were used to assess the differences in the decline of lung function, health-related quality of life, and quantitative CT indexes between these two groups. Zero-inflated negative binomial regressions were used to evaluate the rates of acute respiratory exacerbations between the groups. RESULTS: Among participants with mild-to-moderate COPD, 428 (43.3%) exhibited emphysema on CT scans. The annual decline in FEV1 was -56.1 mL/y for the EC group and -46.9 mL/y for the NEC group, with a nonsignificant between-group difference of 9.1 mL/y (95% CI, -24.0 to 5.7 mL/y). The rate of emphysema progression in the EC group was significantly lower than in the NEC group (natural logarithm(%LAA-950), -0.173%; 95% CI, -0.252% to -0.094%). The EC group also showed a more pronounced annual increase in the St. George's Respiratory Questionnaire score (0.9 points) compared with the NEC group. The EC group had a higher rate of acute respiratory exacerbations (0.36 per person-year) than the NEC group (0.25 per person-year), with a rate ratio of 1.42 (95% CI, 1.27-1.54). INTERPRETATION: The EC group did not have accelerated rates of decline in FEV1, but they experienced significantly worse health-related quality of life and a higher rate of acute respiratory exacerbations. The nonemphysema subtype demonstrated increased emphysema progression. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT01969344; URL: www. CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Yang H, Yang Y, Wang F, et al. Clinical and Prognostic Differences in Mild to Moderate COPD With and Without Emphysema. Chest. 2024. PMID: 39454999. doi:10.1016/j.chest.2024.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。